8- bromo- 2,3,4,5- tetrahydro- 3- methyl- 5- phenyl- 1H-3-benzazepin-7-ol

stereoselective antagonist of dopamine receptor

Also Known As:

1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-; 1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (S-isomer); 7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide; SK&F 83566; SK&F-83566; SKF 83566

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: 168
        8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol: 2

Experts

1.	Dehpour, Ahmad Reza: 1 article (03/2000)
2.	Fakhrian, Rashin: 1 article (03/2000)
3.	Mohagheghi, Massoud: 1 article (03/2000)
4.	Samini, Morteza: 1 article (03/2000)

Related Diseases

1.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/01/2000 - "Pretreatment with sulpiride (5, 10 mg/kg, i.p.) and SKF 83566 (0.4, 0.8 mg/kg, i.p.) attenuated the potentiating effects of l-dopa on withdrawal symptoms significantly. " 03/01/2000 - "SKF 83566, D(1) dopamine antagonist (0.4, 0.8 mg/kg, i.p.) and sulpiride, D(2) dopamine antagonist (5, 10 mg/kg, i.p.) when used alone, also produced inhibitory effects on naloxone-induced morphine withdrawal symptoms. "
2.	Catalepsy 03/01/1992 - "The effects of dopamine D1 antagonists SCH 23390 or SK&F 83566 (at SC doses of 0.00, 0.01, 0.05, and 0.1 mg/kg) were tested for 2 h on bar and cling catalepsy and the dorsal immobility response. "

Related Drugs and Biologics

1.	Dopamine Antagonists
2.	Sulpiride (neogama)
3.	Naloxone (Narcan)
4.	Morphine (MS Contin)
5.	Levodopa (L Dopa)
6.	Dopamine (Intropin)
7.	SCH 23390